1
|
Bronzwaer ASGT, Bogert LWJ, Westerhof BE, Piek JJ, Daemen MJAP, van Lieshout JJ. Abnormal haemodynamic postural response in patients with chronic heart failure. ESC Heart Fail 2017; 4:146-153. [PMID: 28451451 PMCID: PMC5396043 DOI: 10.1002/ehf2.12127] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2016] [Revised: 10/17/2016] [Accepted: 11/08/2016] [Indexed: 12/12/2022] Open
Abstract
Aim The objective was to evaluate in treated heart failure (HF) patients whether multidrug therapy interferes with the cardiovascular autonomic response to postural stress. Methods and results Blood pressure (BP; Finapres), heart rate (HR), stroke volume, and total peripheral resistance (TPR) responses to standing up were measured in 33 HF patients and 10 healthy age‐matched controls. Ten hypertensive (HT) patients treated with a similar combination of drugs but without heart failure served as reference subjects to account for use of medication. Frequency domain measures of HR and BP variability were calculated as correlates of cardiovascular autonomic function. Postural hypotension was found in 16 out of 33 HF patients independently from New York Heart Association functional class. In HF patients vs. HT patients and healthy controls the haemodynamic postural response was abnormal with a large initial BP fall and a slackened reflex increase in TPR resulting in inadequate BP recovery. HR and BP variability were normal in HT patients and healthy controls but attenuated in HF patients. The magnitude of the postural HR, stroke volume, and TPR responses as well as HR and BP variability was inversely related to the New York Heart Association class. Conclusions In HF patients, the autonomic vasomotor response to postural stress is abnormal, more pronounced with increasing disease severity, and frequently associated with overt postural hypotension. These phenomena appear related to the cardiac condition rather than treatment.
Collapse
Affiliation(s)
- Anne-Sophie G T Bronzwaer
- Department of Internal Medicine, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands.,Laboratory for Clinical Cardiovascular Physiology, Centre for Heart Failure Research, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands
| | - Lysander W J Bogert
- Department of Internal Medicine, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands.,Laboratory for Clinical Cardiovascular Physiology, Centre for Heart Failure Research, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands
| | - Berend E Westerhof
- Laboratory for Clinical Cardiovascular Physiology, Centre for Heart Failure Research, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands.,Department of Pulmonary DiseasesVU University Medical CentreAmsterdamThe Netherlands
| | - Jan J Piek
- AMC Heart Center, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands
| | - Mat J A P Daemen
- Department of Pathology, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands
| | - Johannes J van Lieshout
- Department of Internal Medicine, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands.,Laboratory for Clinical Cardiovascular Physiology, Centre for Heart Failure Research, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands.,MRC/Arthritis Research UK Centre for Musculoskeletal Ageing Research, School of Life SciencesUniversity of Nottingham Medical School, Queen's Medical CentreNottinghamUK
| |
Collapse
|
2
|
Chatterjee K, Rouleau JL, Massie BM. Hydralazine in chronic CHF. ACTA MEDICA SCANDINAVICA. SUPPLEMENTUM 2009; 652:99-113. [PMID: 6949469 DOI: 10.1111/j.0954-6820.1981.tb06797.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
In summary, there investigations indicate that oral hydralazine produces beneficial hemodynamic effects in patients with chronic CHF. These favorable hemodynamic response are observed in the presence or absence of mechanical defects, such as mitral or aortic regurgitation. The predominant hemodynamic effects of hydralazine are substantial increase in CO and SV with decreased systemic vascular resistance. These investigations further suggest that hydralazine therapy not only improves resting cardiac performance, but also cardiac performance during exercise. There is also evidence that improved cardiac performance is sustained at least in some patients during maintenance hydralazine therapy. The impact of hydralazine therapy on the long term prognosis of patients with refractory CHF, however, remains unknown. Nevertheless, the preliminary retrospective studies suggest that in certain subsets of patients with severe chronic CHF, such therapy may provide a better prognosis compared to that expected with conventional therapy.
Collapse
|
3
|
|
4
|
|
5
|
Digitalis and Non-ACE Inhibitor Vasodilators in Heart Failure. Cardiol Clin 1989. [DOI: 10.1016/s0733-8651(18)30460-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
6
|
Natarajan D, Khurana TR, Karhade V, Nigam PD. Sustained hemodynamic effects with therapeutic doses of intravenous nitroglycerin in congestive heart failure. Am J Cardiol 1988; 62:319-21. [PMID: 3135741 DOI: 10.1016/0002-9149(88)90236-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- D Natarajan
- Department of Cardiology, Dr. Ram Manohar Lohia Hospital, New Delhi, India
| | | | | | | |
Collapse
|
7
|
Abstract
Nitroglycerin has long been a mainstay of the treatment of ischemic cardiac pain. The introduction of transdermal formulations and in particular the development of controlled methods of delivery have been responsible for the renaissance of clinical interest in this simple and effective treatment. The pathophysiologic abnormality accompanying myocardial ischemia affords a natural theater for the exhibition of the therapeutic utility of these preparations and methods. The means whereby nitrates induce relaxation of vascular smooth muscle are not entirely clear, but their pharmacodynamic activities are perfectly plain. In the doses used in clinical practice, nitrates exert their predominant hemodynamic effects and therapeutic benefits through their peripheral vasodilator activities. This is particularly marked in veins, although in higher doses nitrates also dilate the larger systemic and coronary arteries. Criticisms of the efficacy of transdermal formulations of nitrates in the treatment of angina pectoris have arisen largely from uncritical acceptance of a small number of studies of questionable methodologic validity. Large-scale general practice studies have invariably found that transdermal nitrate delivery systems improve the quality of life in ambulant patients: anginal attacks are reduced with a minimum of side effects. The widespread acceptance of this novel form of drug delivery has stimulated its application in other therapeutic avenues. The efficacy of transdermal nitroglycerin in the suppression of silent ischemic attacks has been demonstrated. The maintenance of benefit initiated by intravenous nitroglycerin in patients with unstable angina also broadens the use of this method of nitrate delivery. In patients with acute myocardial infarction, whether complicated by left ventricular failure or not, the nitrates, and transdermal nitroglycerin in particular, appear to hold considerable promise. Improvement of hemodynamic abnormalities may cause reduction in infarct size and fewer life-threatening arrhythmias. Even survival may be extended. The utility of transdermal nitrates in the treatment of severe chronic heart failure is less certain. But the use of higher doses and an interval regimen of administration may hold promise for such patients. Naturally, more information is required before the overall therapeutic profile of this new method of controlled nitroglycerin delivery across the whole spectrum of coronary heart disease can be fully described. Fortunately, the high level of efficacy and safety of transdermal nitroglycerin demonstrated in the majority of reported studies encourages the pursuit of such an important therapeutic target.
Collapse
|
8
|
Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547-52. [PMID: 3520315 DOI: 10.1056/nejm198606123142404] [Citation(s) in RCA: 1863] [Impact Index Per Article: 49.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
To evaluate the effects of vasodilator therapy on mortality among patients with chronic congestive heart failure, we randomly assigned 642 men with impaired cardiac function and reduced exercise tolerance who were taking digoxin and a diuretic to receive additional double-blind treatment with placebo, prazosin (20 mg per day), or the combination of hydralazine (300 mg per day) and isosorbide dinitrate (160 mg per day). Follow-up averaged 2.3 years (range, 6 months to 5.7 years). Mortality over the entire follow-up period was lower in the group that received hydralazine and isosorbide dinitrate than in the placebo group. This difference was of borderline statistical significance. For mortality by two years, a major end point specified in the protocol, the risk reduction among patients treated with both hydralazine and isosorbide dinitrate was 34 percent (P less than 0.028). The cumulative mortality rates at two years were 25.6 percent in the hydralazine--isosorbide dinitrate group and 34.3 percent in the placebo group; at three years, the mortality rate was 36.2 percent versus 46.9 percent. The mortality-risk reduction in the group treated with hydralazine and isosorbide dinitrate was 36 percent by three years. The mortality in the prazosin group was similar to that in the placebo group. Left ventricular ejection fraction (measured sequentially) rose significantly at eight weeks and at one year in the group treated with hydralazine and isosorbide dinitrate but not in the placebo or prazosin groups. Our data suggest that the addition of hydralazine and isosorbide dinitrate to the therapeutic regimen of digoxin and diuretics in patients with chronic congestive heart failure can have a favorable effect on left ventricular function and mortality.
Collapse
|
9
|
Chevigné M, Rigo P, Kassab A, Kulbertus H. Evaluation of the effects of molsidomine by cardiac equilibrium blood pool scintigraphy. Am Heart J 1985; 109:658-61. [PMID: 3838403 DOI: 10.1016/0002-8703(85)90674-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
We have used equilibrium gated blood pool scintigraphy to evaluate the hemodynamic effects and duration of action of molsidomine, a new peripheral vasodilator antianginal drug, after sublingual administration (4 mg) in five patients with heart failure. The following parameters were studied at rest and 10, 60, and 240 minutes after drug administration: left and right ventricular ejection fractions, end-diastolic and end-systolic volumes, stroke volume, heart rate, and cardiac index. Systolic and diastolic blood pressures were determined by cuff measurement. Statistically significant (p less than 0.05) changes were observed after 10 minutes for left ventricular ejection fraction (+26.2%), left and right end-diastolic volume (-12.4% and -15.2%), left ventricular end-systolic volume (-15%), and cardiac index (+7.9%); after 60 minutes for left ventricular ejection fraction (+49%), left ventricular systolic volume (+30.5%), cardiac index (+29.7%), systolic blood pressure (-7.9%), and right ventricular end-diastolic volume (-14.3%); and after 240 minutes for cardiac index (+23.9%), systolic blood pressure (-6.3%), and right ventricular ejection fraction (+23.1%). No changes in heart rate were observed. No patient experienced any side effect. We conclude that the hemodynamic improvement observed with molsidomine can be prolonged and results both from preload and afterload reduction.
Collapse
|
10
|
Breen EG, Mulhall D, Keogh JA. Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator. Eur J Clin Pharmacol 1985; 28:381-6. [PMID: 4029244 DOI: 10.1007/bf00544354] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Twenty patients with uncontrolled hypertension were treated with pinacidil for a mean period of 43 weeks (range 10-63 weeks). All patients achieved and maintained significant reductions in blood pressure. The supine blood pressure at baseline was 184/116 mmHg; after one week it was 161/95 mmHg and at 43 weeks it was 138/79 mmHg. The mean dose of pinacidil was 30 mg/day. There was no significant difference between the two groups with respect to the dose of pinacidil or the blood pressure response. Pulse rate and weight remained stable for the group as a whole. Five patients were not taking beta-blockers. The mean baseline pulse rate for this group was 78 beats/min and when maintained on pinacidil it was 82 beat/min (NS). Six patients were not taking diuretics. The mean baseline weight for this group was 78.5 kg and while maintained on pinacidil it was 79.2 kg (NS). There was no occurrence of oedema, hirsutism or first dose phenomenon. The mean glomerular filtration rate and renal plasma flow for the renal plasma flow for the renal group was 35.4 ml/min and 192.3 ml/min before pinacidil and after six months they were 32.7 ml/min and 183.2 ml/min (NS) respectively. Six patients experienced minor side-effects. We conclude that pinacidil is a potent, well tolerated antihypertensive agent which merits further study.
Collapse
|
11
|
Abstract
This article seeks to make clear the basic differences in the treatment of heart failure between therapeutic maneuvers that are aimed at improving the mechanical loading conditions of the heart and those that are aimed at augmenting the fundamental contractile or inotropic state of the myocardium. Emphasis is placed on recognizing that treatment expectations must be viewed within an age- or maturity-dependent framework, since a diminished margin of cardiocirculatory reserve exists in the smallest and youngest patients that limits the extent of benefit that may be derived from diverse treatment approaches.
Collapse
|
12
|
Rajfer SI, Demma FJ, Goldberg LI. Sustained beneficial hemodynamic responses to large doses of transdermal nitroglycerin in congestive heart failure and comparison with intravenous nitroglycerin. Am J Cardiol 1984; 54:120-5. [PMID: 6430054 DOI: 10.1016/0002-9149(84)90315-1] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The hemodynamic effects of a new transdermal preparation of nitroglycerin were evaluated in 9 patients with chronic congestive heart failure (CHF). A graded infusion of nitroglycerin was administered initially to establish the dose-response relation for nitroglycerin and estimate the dose of topical nitroglycerin to be applied. Significant hemodynamic improvement was observed 0.5 to 1.0 hour after the cutaneous application of the nitroglycerin-impregnated polymer. The peak effect occurred at 6 hours, with the left ventricular filling pressure decreasing from 24 +/- 2 to 18 +/- 1 mm Hg (mean +/- standard error of the mean) (p less than 0.01) and the cardiac index increasing from 2.0 +/- 0.2 to 2.6 +/- 0.2 liters/min/m2 (p less than 0.01). The systemic vascular resistance decreased from 1,860 +/- 198 to 1,531 +/- 162 dynes s cm-5 (p less than 0.01). Heart rate and mean arterial pressure were unchanged. Significant hemodynamic benefit was observed for 24 hours, and no rebound deterioration occurred upon withdrawal of the drug. The average dose of transdermal nitroglycerin applied was 51 +/- 6 cm2 (1.7 +/- 0.2 mg/kg; 6 of the 9 patients received 64 cm2). Thus, topical application of a new nitroglycerin-impregnated polymer induces an improvement in cardiac performance that is sustained for 24 hours in patients with chronic CHF. However, substantial doses of the drug may be required to produce a satisfactory hemodynamic response in most patients with CHF.
Collapse
|
13
|
Hendry WG, Comerford MB, Besterman EM. A dose response study with oral prenalterol in patients with chronic congestive cardiac failure. Clin Cardiol 1984; 7:23-8. [PMID: 6705284 DOI: 10.1002/clc.4960070106] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Prenalterol is an orally active cardioselective beta agonist, with a long half-life. Previous studies have confirmed its inotropic activity following intravenous infusion in patients with heart failure. It has little chronotropic activity and no significant arrhythmogenicity. We have studied the response to sustained-release oral prenalterol given over four weeks at doses of 20, 40, 100, and 200 mg daily in 10 patients with New York Heart Association class II and III heart failure due to ischemic heart disease. All were in sinus rhythm and already receiving diuretics and digoxin. The drug was well tolerated and without side effects. Nine patients showed a dose-related improvement in their exercise tolerance as measured on the treadmill, up to a dose of 100 mg daily, with a significant increase in estimated oxygen uptake. There was a dose-related reduction in maximum heart rate, systolic blood pressure, and rate-pressure product during exercise, which is suggestive of a reduction in myocardial oxygen consumption. We conclude that prenalterol improves exercise tolerance without any significant cardiovascular or other side effects, and produces a clinically relevant and sustained improvement in patients with chronic heart failure. M-mode echocardiographic measurements of left ventricular dimension and function at rest did not show any change during the study.
Collapse
|
14
|
Ports TA, Chatterjee K, Wilkinson P, Avakian D, Parmley WW. Trimazosin in chronic congestive heart failure: improved left ventricular function at rest and during exercise. Am Heart J 1983; 106:1036-1042. [PMID: 6139004 DOI: 10.1016/0002-8703(83)90649-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
The hemodynamic effects of the oral vasodilator trimazosin were evaluated in patients with chronic congestive heart failure (CHF), initially over a 72-hour period (13 patients), and after 3 months of maintenance therapy (seven patients). During the initial evaluation, cardiac index and stroke work index increased an average of 24% and 37% respectively, and pulmonary capillary wedge pressure decreased by 26%. These beneficial hemodynamic effects were maintained during supine bicycle exercise. After 3 months of maintenance therapy, cardiac index (+30%) and stroke work index (+38%) remained elevated, and pulmonary capillary wedge pressure was lower (-38%). Improved hemodynamics during exercise were also seen after maintenance therapy. Withdrawal of trimazosin was associated with deterioration in hemodynamics and left ventricular function. Thus trimazosin has the potential to cause sustained improvement in left ventricular function, both at rest and during exercise, in patients with chronic CHF.
Collapse
|
15
|
Abstract
Vasodilator agents are relatively new additions to the armamentarium for the management of patients with congestive heart failure. Myocardial failure, irrespective of the aetiology, tends to create a vicious cycle characterised by reduced cardiac output and elevated systemic vascular resistance, which further decrease cardiac output by increasing left ventricular ejection impedance. The rationale for the use of vasodilators is to interrupt the vicious cycle by decreasing the left ventricular ejection impedance by peripheral vasodilatation. Although most vasodilator agents produce qualitatively similar haemodynamic responses, quantitatively their haemodynamic effects differ considerably. Knowledge of the haemodynamic effects of the various vasodilators helps in the selection of a particular drug for the management of such patients. This article reviews the mechanisms of action, haemodynamic effects, pharmacokinetics, clinical usage and adverse effects of non-parenteral vasodilator agents currently available for the management of patients with chronic heart failure.
Collapse
|
16
|
Unverferth DV, Mehegan JP, Magorien RD, Unverferth BJ, Leier CV. Regression of myocardial cellular hypertrophy with vasodilator therapy in chronic congestive heart failure associated with idiopathic dilated cardiomyopathy. Am J Cardiol 1983; 51:1392-8. [PMID: 6682617 DOI: 10.1016/0002-9149(83)90318-1] [Citation(s) in RCA: 32] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Forty-nine patients with idiopathic dilated cardiomyopathy (IDC) were evaluated to determine the hemodynamic and morphologic effects of vasodilator therapy. Hydralazine (225 mg/day, H), isosorbide dinitrate (160 mg/day, I), and combination H + I therapy were compared with placebo (P) at baseline and after 3 months of continuous therapy. Thirty-three randomly assigned patients completed the study. Hemodynamic parameters included the echocardiographic percent change of left ventricular diameter (% delta D), the systolic time intervals ratio of preejection period to left ventricular ejection time (PEP/LVET), the pulmonary capillary wedge pressure, mean pulmonary artery pressure, cardiac index, systemic vascular resistance, and pulmonary vascular resistance. An endomyocardial biopsy was performed at baseline and after 3 months; the myocardial cell diameter of 50 cells per biopsy was measured. During the 3-month study 5 patients died; there was not a significant difference among the groups in the number of deaths. The % delta D and PEP/LVET did not change in the P or I groups but did improve significantly from baseline in the H and H + I groups. The pulmonary capillary wedge and mean pulmonary artery pressures and the pulmonary vascular resistance did not change in the P or H groups but did decrease significantly in the I and H + I groups. The P and I groups did not have improvement in systemic vascular resistance or cardiac index, whereas the H group had a decrease in systemic vascular resistance and an increase in cardiac index from 2.5 +/- 0.4 to 3.1 +/- 0.4 liters/min/m2 (p less than 0.05). The H + I group also had a decrease in systemic vascular resistance; the cardiac index increased from 2.3 +/- 0.4 to 3.1 +/- 0.4 liters/min/m2 (p less than 0.01). Myocardial cell diameter did not change in the P or I group. Cell diameter of the H group decreased from 25.4 +/- 3.1 microns at baseline to 23.1 +/- 3.8 microns (p less than 0.05) after 3 months of continuous therapy. The H + I group decreased its cell diameter from 23.9 +/- 3.7 to 22.2 +/- 2.2 microns (p less than 0.05). Compared with P and H, patients treated with I alone or H + I had a significant reduction of preload. In contrast to P and I, H alone and H + I elicited improvement in parameters of inotropy and afterload, and this improvement was accompanied by a reduction in cell diameter. Chronic therapy of heart failure with H and H + I effects a persistent augmentation of cardiac function and improvement of myocardial cellular morphology.
Collapse
|
17
|
Holmes DG, Bogers WA, Wideroe TE, Huunan-Seppala A, Wideroe B. Endralazine, a new peripheral vasodilator: absence of effect of acetylator status on antihypertensive effect. Lancet 1983; 1:670-1. [PMID: 6132036 DOI: 10.1016/s0140-6736(83)91967-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
50 patients with confirmed hypertension were treated with endralazine, a new peripheral vasodilator, in addition to the beta-blocker, pindolol, to which they had not responded adequately. The blood pressure was lowered from 173/115 mm Hg to 143/87 mm Hg in the 34 slow acetylators and from 175/111 mm Hg to 140/84 mm Hg in the 16 fast acetylators. The dosages of both pindolol and endralazine were the same in both groups. It is concluded that the acetylator phenotype does not affect the therapeutic efficacy or dosage requirement of endralazine. It is suggested that this is because endralazine is metabolised mainly by hydrazone formation and only to a minor extent by acetylation.
Collapse
|
18
|
Kino M, Hirota Y, Yamamoto S, Sawada K, Moriguchi M, Kotaka M, Kubo S, Kawamura K. Cardiovascular effects of a newly synthesized cardiotonic agent (TA-064) on normal and diseased hearts. Am J Cardiol 1983; 51:802-10. [PMID: 6829441 DOI: 10.1016/s0002-9149(83)80137-4] [Citation(s) in RCA: 37] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
A new inotropic agent, TA-064, (-)-alpha-(3,4-dimethoxyphenethylaminomethyl)-4-hydroxybenzylalcohol, was shown to have strong effects in experimental animals. Its effectiveness and associated adverse effects were tested in humans invasively (n = 6) and noninvasively (n = 17). Increasing doses of intravenous infusion (1, 2, and 4 micrograms/kg/min) increased plasma levels to 15, 35, and 82 ng/ml, respectively, resulting in marked increases in the peak rate of left ventricular pressure rise (dP/dt) (1,450 +/- 63 to 3,042 +/- 349 mm Hg/s) (mean +/- standard error of the mean [SEM], p less than 0.01) and the ratio of dP/dt to left ventricular pressure at a developed pressure of 40 mm Hg (25 +/- 3 to 39 +/- 2 s-1) (p less than 0.01), with a reduction in left ventricular end-diastolic pressure (12 +/- 2 to 4 +/- 1 mm Hg) (p less than 0.01). Minimal or no changes were seen in heart rate and left ventricular systolic pressure. After a single oral dose (10 mg), the plasma level reached its peak at 90 minutes (16 +/- 9 ng/ml, n = 17). A positive inotropic effect was confirmed echocardiographically in both healthy volunteers (n = 8) and patients with congestive heart failure (CHF) (n = 9) who were maximally treated with conventional regimens: increase in mean velocity of circumferential fiber shortening (healthy volunteers: 1.29 +/- 0.05 to 1.60 +/- 0.11 circ/s [p less than 0.05]; patients with CHF: 0.69 +/- 0.08 to 0.93 +/- 0.09 circ/s [p less than 0.01]), ejection fraction (healthy volunteers: 68 +/- 2 to 75 +/- 2% [p less than 0.05], patients with CHF: 37 +/- 4 to 45 +/- 5% [p less than 0.01]) without change in heart rate. The cardiac index was increased only in the CHF group (2.71 +/- 0.22 to 3.21 +/- 0.24 liters/min/m2) (p less than 0.05). No significant untoward effects were observed. Thus TA-064 is a potent inotropic agent and can be used either parenterally or orally. Salutary effects can be expected in patients with congestive heart failure who are treated with digitalis and diuretic agents.
Collapse
|
19
|
Abstract
Congestive heart failure (CHF) is a complex clinical entity which is still little understood pathophysiologically. Unless it is in the intractable state it responds well to therapy. It has been known for many years that the peripheral circulation can be dramatically altered when CHF is progressively and rapidly developing and worsening. As compensation develops, these changes gradually return to normal. We have long been studying the digital circulation of patients with CHF and have been impressed with the changes in the behavior of the peripheral blood vessels in these patients.
Collapse
|
20
|
Applefeld MM, Newman KA, Grove WR, Sutton FJ, Roffman DS, Reed WP, Linberg SE. Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure. Am J Cardiol 1983; 51:455-8. [PMID: 6823859 DOI: 10.1016/s0002-9149(83)80079-4] [Citation(s) in RCA: 69] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The use of outpatient dobutamine infusions by a small, portable infusion pump in 3 patients with intractable congestive heart failure (CHF) is described. With this therapy left ventricular function improved and CHF resolved in each. Tolerance to dobutamine was obviated by giving infusions twice weekly. Except for 3 mild infections around the catheter exit site, there have been no complications of this therapy is 58 cumulative patient weeks.
Collapse
|
21
|
Nathan M, Rubin SA, Siemienczuk D, Swan HJ. Effects of acute and chronic minoxidil administration on rest and exercise hemodynamics and clinical status in patients with severe, chronic heart failure. Am J Cardiol 1982; 50:960-6. [PMID: 7137047 DOI: 10.1016/0002-9149(82)90402-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The effects of acute and chronic oral administration of the vasodilator minoxidil on hemodynamics, oxygen consumption, exercise performance, and clinical status were investigated in 10 patients with severe, chronic heart failure refractory to digitalis and diuretic therapy. The cardiac index was 1.99 +/- 0.38 liters/min/m2 at rest and 2.88 +/- 0.79 at symptom-limited maximal exercise on conventional therapy, compared with 2.64 +/- 0.33 liters/min/m2 at rest and 3.55 +/- 0.84 at maximal exercise after short-term minoxidil administration (p less than 0.02, control versus minoxidil at both rest and exercise). Stroke volume was increased after minoxidil treatment, without significant effect on heart rate. Systemic vascular resistance was decreased by minoxidil from 2,050 +/- 722 to 1,325 +/- 374 dynes . s/cm-5 at rest and from 1,500 +/- 830 to 1,206 +/- 589 dynes . s/cm-5 at maximal exercise (p = 0.01, control versus minoxidil). No significant effect was observed on left ventricular filling, right atrial, or mean pulmonary arterial pressure, but pulmonary vascular resistance decreased both at rest and on exercise (p less than 0.05). Maximal exercise oxygen consumption increased from 8.9 +/- 3.2 ml/kg/min on conventional therapy to 10.5 +/- 2.4 on minoxidil therapy (p less than 0.03), median maximal exercise work load increased from 25 to 50 W and medium exercise duration increased from 6.0 to 9.0 minutes. On chronic minoxidil administration all 5 patients who completed a scheduled 6 week follow-up showed symptomatic improvement. However, worsening edema developed in all patients, requiring increased diuretic dosage and close supervision. Symptoms of ischemic heart disease worsened in 2 of 10 patients. We tentatively conclude that minoxidil may be a useful vasoactive agent in the pharmacologic therapy of severe chronic heart failure.
Collapse
|
22
|
|
23
|
Miller RR, Fennell WH, Young JB, Palomo AR, Quinones MA. Differential systemic arterial and venous actions and consequent cardiac effects of vasodilator drugs. Prog Cardiovasc Dis 1982; 24:353-74. [PMID: 6801728 DOI: 10.1016/0033-0620(82)90019-6] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
24
|
Fitzgerald DJ, O'Callaghan WG, O'Malley K, Horgan J, O'Brien E. Clinical and haemodynamic responses to captopril and hydralazine in chronic congestive heart failure: the importance of preload reduction. Br J Clin Pharmacol 1982; 14 Suppl 2:217S-222S. [PMID: 6753903 PMCID: PMC1427535 DOI: 10.1111/j.1365-2125.1982.tb02080.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
1 Although many vasodilators are effective in the treatment of severe congestive heart failure, there have been few comparative studies of these drugs. We compared the acute haemodynamic effects of captopril and hydralazine in 11 patients with congestive cardiac failure unresponsive to diuretics and digoxin. Both drugs increased resting cardiac index, although this effect appeared more pronounced for hydralazine (33% v 23%). Captopril reduced pulmonary capillary wedge pressure (-8 mm Hg, p less than 0.01) which decreased only slightly on hydralazine. 2 Long-term treatment was then started on the dose found effective during acute administration. Each drug was given for eight weeks. Exercise tolerance improved with both drugs, the increase during the hydralazine phase correlating with the increase in cardiac index at rest (r = 0.75; p less than 0.05). Clinical improvement appeared more definite on captopril than on hydralazine, however. This improvement was maintained during the captopril phase only in those patients who had a greater than 25% reduction in pulmonary capillary wedge pressure in the acute study.
Collapse
|
25
|
Hecht HS, Karahalios SE, Schnugg SJ, Ormiston JA, Hopkins JM, Rose JG, Singh BN. Improvement in supine bicycle exercise performance in refractory congestive heart failure after isosorbide dinitrate: radionuclide and hemodynamic evaluation of acute effects. Am J Cardiol 1982; 49:133-40. [PMID: 6274182 DOI: 10.1016/0002-9149(82)90287-9] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
26
|
Komajda M, Eugene M, Evans J, Drobinski G, Laurenceau JL, Grosgogeat Y. Long-term treatment of congestive heart failure with captopril. Br J Clin Pharmacol 1982; 14 Suppl 2:223S-229S. [PMID: 6753904 PMCID: PMC1427509 DOI: 10.1111/j.1365-2125.1982.tb02081.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
1 The efficacy of the converting-enzyme inhibitor captopril in the management of severe congestive heart failure was assessed in 14 patients over 360-885 days by clinical evaluation, M-mode echocardiography, systolic time intervals, plasma renin activity, and plasma aldosterone. 2 As compared with baseline values, a significant reduction was observed in heart rate, mean arterial pressure, left ventricular end-diastolic and end-systolic diameters, left ventricular pre-ejection period, tension time index, body weight, and plasma aldosterone. Significant increases in left ventricular ejection time and fractional circumferential shortening (p less than 0.01) were also observed. 3 The functional and haemodynamic benefit provided by captopril was therefore sustained during long-term therapy without severe untoward effects or attenuation.
Collapse
|
27
|
Walsh WF, Greenberg BH. Results of long-term vasodilator therapy in patients with refractory congestive heart failure. Circulation 1981; 64:499-505. [PMID: 7261282 DOI: 10.1161/01.cir.64.3.499] [Citation(s) in RCA: 72] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The long-term effects of vasodilator therapy with oral hydralazine and long-acting nitrates were studied in 34 patients with refractory heart failure. Seven patients who had marginal hemodynamic improvement despite optimal hydralazine therapy were not maintained on vasodilators, and eight who had a favorable hemodynamic response subsequently discontinued hydralazine therapy because of side effects. Of these 15 patients, four (27%) died and 11 remained in New York Heart Association functional class II or IV at a mean follow-up of 10 +/- 2 months (SEM). The 19 patients who received chronic therapy for 8 +/- 2 months were divided into nine late responders (47%), who improved to functional class I or II, and 10 late nonresponders (53%), who remained in functional class III or IV. Only one of the nine late responders (11%) died, compared with seven of the 10 late nonresponders (70%) (p less than 0.01). The actuarially determined survival at 1 year was 100% for late responders and 13 +/- 12% for late nonresponders (p less than 0.01). No clinical variable could distinguish late responders from late nonresponders. Hemodynamic variables measured before vasodilator therapy showed that late responders had a lower mean right atrial pressure (8 +/- 1 vs 17 +/- 3 mm Hg, p less than 0.01) and lower mean pulmonary artery wedge pressure (20 +/- 2 vs 30 +/- 2 mm Hg, p less than 0.005), higher stroke, volume index (27 +/- 2 vs 20 +/- 1 ml/m2, p less than 0.005) and higher stroke work index (32 +/- 4 vs 19 +/- 2 g-m/m2, p less than 0.01) than late nonresponders. There were no significant differences in the acute response to vasodilators between the two groups. We conclude that (1) a substantial portion of patients with refractory congestive heart failure either do not have a beneficial response to vasodilator therapy or discontinue it because of side effects; (2) about half of the patients who are maintained on chronic vasodilator therapy (or about one-fourth of the patients in whom therapy is initiated) had sustained clinical benefit; and (3) the initial hemodynamics, but not the clinical variables, are predictive of late mortality and late clinical response. Patients with evidence of more severe left ventricular dysfunction have an unfavorable course.
Collapse
|
28
|
Chatterjee K, Rubin SA, Ports TA, Parmley WW. Influence of oral prazosin therapy on exercise hemodynamics in patients with severe chronic heart failure. Am J Med 1981; 71:140-6. [PMID: 7246571 DOI: 10.1016/0002-9343(81)90277-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
In 10 patients with severe chronic congestive heart failure, changes in hemodynamic and cardiac performance at rest and during exercise were evaluated following short-term oral prazosin therapy. The median total dose of prazosin was 43 mg (range 23 to 95 mg) and the median duration of therapy was 47 hours (range 18 to 92 hours). Prazosin increased cardiac output and stroke volume significantly during exercise (both p less than 0.05) but not at rest (both p greater than 0.10). The magnitude of the increase in pulmonary capillary wedge pressure during exercise with the addition of prazosin was also significantly less than that during conventional therapy, suggesting improved cardiac performance during exercise. Peak oxygen consumption, peak lactate concentration and rate of disappearance of the increased concentration of lactate induced by exercise, however, remained unchanged following prazosin therapy. These findings suggest that short-term prazosin therapy, as other vasodilators, improves cardiac performance during exercise but may not necessarily influence oxygen consumption.
Collapse
|
29
|
Drexler H, Löllgen H, Just H. Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure. KLINISCHE WOCHENSCHRIFT 1981; 59:647-54. [PMID: 7253539 DOI: 10.1007/bf02593856] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The hemodynamic benefits of combined administration of prenalterol (P) with hydralazine (H) were evaluated in ten patients with severe chronic heart failure. Single administration of 100 mg H increased cardiac index (CI) from 2.3 to 3.0 l/min/m2, whereas pulmonary capillary wedge pressure (PWC) remained unchanged. After 3--4 weeks of treatment with 200 mg H hemodynamic improvementt was maintained (CI: 2.9 l/min/m2). Additional administration of P caused further augmentation of CI (3.3 l/min/m2). After long-term treatment with the combination of H and P sustained augmentation of CI (3.2 l/min/m2), and, furthermore, a slight but significant decrease of PCW were observed (p less than 0.05 vs. chronic single H-therapy). Five patients were able to perform exercise testing; H improved maximal exercise capacity and exercise hemodynamics in three patients. Further improvemen was observed after combined treatment (H + P) in three of five patients. It is concluded, the prenalterol may enhance the effectiveness of hydralazine therapy in congestive heart failure by providing concomitantly the principal actions of the vasodilator and positive inotropic agent used separately. Furthermore, the results indicate that oral long-term administration of hydralazine and prenalterol can produce sustained beneficial improvement.
Collapse
|
30
|
|
31
|
Awan NA, Lee G, DeMaria AN, Mason DT. Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy. Am Heart J 1981; 101:541-7. [PMID: 7223594 DOI: 10.1016/0002-8703(81)90219-2] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
To evaluate whether long-term administration of the oral vasodilator, prazosin, in the ambulatory therapy of chronic refractory congestive heart failure (CHF) results in gradual attentuation of its marked salutary peripheral circulatory relaxing actions, 16 coronary heart failure patients receiving chronic prazosin, 16 mg daily, were assessed for the development of vasodilator tolerance for 12 months. In six of these patients such tolerance was documented after 7 months which was readily surmountable, thereby allowing continuation of effective chronic prazosin therapy. Each of the six tolerance patients underwent four forearm plethysmography studies: prior to chronic prazosin (study I; 4.0 mg study dose), after 7 months prazosin (study II; 4.0 mg), repeated following 1 additional week on higher effective prazosin dose of 32 mg daily (study III; 8.4 mg), and following 2 weeks of prazosin withdrawal (study IV; 4.0 mg). The prazosin study dose increased forearm blood flow, decreased forearm vascular resistance and venous tone in studies I, III, and IV; these variables were unchanged by prazosin in study II. Despite vasodilator tolerance to the initial daily dosage at 7 months (study II), symptomatic effectiveness and improved cardiac performance were sustained throughout the entire 12 months of chronic prazosin therapy by increasing dosage (study III) and brief interruption of the vasodilator (study IV) (NYHA class IV pre-prazosin symptoms improved to class 2.7 at 3 months, class 2.4 at 6 months, and class 2.5 at 12 months chronic prazosin). This study showed that prazosin vasodilator tolerance occurred in approximately one third of CHF patients after several months of chronic prazosin therapy. More importantly, however, the present investigation demonstrated that chronic prazosin symptomatic efficacy can be maintained in such CHF patients by overcoming tolerance with higher effective prazosin dosage or brief prazosin discontinuation.
Collapse
|
32
|
Unverferth DV, Magorien RD, Lewis RP, Leier CV. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1980; 100:622-30. [PMID: 6778182 DOI: 10.1016/0002-8703(80)90226-4] [Citation(s) in RCA: 101] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Dobutamine was given intravenously for three days to 38 patients with congestive cardiomyopathy. The patients were followed by serial determinations of functional class and by non-invasive measurements of left ventricular function-systolic time intervals (PEP/LVET) and echocardiogram (% delta D). The average PEP/LVET declined significantly (p < 0.001) at three days, four and nine weeks, and at 10 months after the discontinuation of dobutamine infusion. Also, 67% (20 of 30) of patients had improvement of the PEP/LVET by greater than -0.04 at seven days. Even two and six months after dobutamine, 58% (15 of 26) and 39% (seven of 18) were improved. Similarly, the % delta D was improved by at least 2% in 60% (18 of 30) at seven days and 55% (16 of 29) at four weeks. At two and six months, 50% (14 of 28) and 42% (10 of 24) were improved. Those patients who did not improve their FC were more likely (five of nine) to have left ventricular free wall thickness (by echocardiogram) less than 0.5 cm./M2. Those who responded usually (22 of 29) had a ventricular wall thickness greater than 0.5 cm./M2. Although the mechanism of the prolonged improvement after a three day infusion of dobutamine is not understood, this study suggests that dobutamine has a role in the therapy of chronic congestive heart failure.
Collapse
|
33
|
Gunnar RM. The role of vasodilating agents in the treatment of chronic heart failure. Angiology 1980; 31:526-32. [PMID: 7001960 DOI: 10.1177/000331978003100803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
34
|
Weber KT, Kinasewitz GT, West JS, Janicki JS, Reichek N, Fishman AP. Long-term vasodilator therapy with trimazosin in chronic cardiac failure. N Engl J Med 1980; 303:242-50. [PMID: 6104295 DOI: 10.1056/nejm198007313030502] [Citation(s) in RCA: 86] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Patients with cardiac failure have a generalized sympathetic vasoconstriction that may impair cardiac function and exercise tolerance. The ability of long-term alpha-receptor blockade and vasodilation with trimazosin (TMZ) to improve exercise capacity was studied in patients with chronic, stable heart failure of varying severity (functional exercise classes B to D). Exercise performance was monitored by respiratory gas exchange and air flow before and after patients were randomized to placebo (13 patients) or TMZ were then followed on treatment for up to 52 weeks. Significant (P less than 0.05) and sustained increases in exercise capacity, oxygen uptake, and oxygen pulse were observed with TMZ treatment in each Class B or C patient and in six of nine Class D patients, and were not observed during treatment with placebo.
Collapse
|
35
|
|
36
|
Ader R, Chatterjee K, Ports T, Brundage B, Hiramatsu B, Parmley W. Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation 1980; 61:931-7. [PMID: 6244906 DOI: 10.1161/01.cir.61.5.931] [Citation(s) in RCA: 253] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The hemodynamic effects of an oral angiotensin-converting enzyme inhibitor, captopril, were evaluated in 10 symptomatic patients with chronic congestive heart failure. In all patients there was a significant increase in cardiac output (average 28%), stroke volume (49%), and stroke work index (26%), along with a decrease in pulmonary capillary wedge pressure (48%), indicating improved left ventricular function. Modest decreases in heart rate and arterial pressure were also observed. In seven patients maintained on captopril therapy, repeat hemodynamic studies at 2 months revealed sustained effects. These beneficial hemodynamic effects were accompanied by clinical improvement and improved exercise tolerance during maintenance therapy. These findings suggest that captopril may be a useful therapeutic adjunct for the long-term management of patients with chronic congestive heart failure.
Collapse
|
37
|
Hindman MC, Slosky DA, Peter RH, Newman GE, Jones RH, Wallace AG. Rest and exercise hemodynamic effects of oral hydralazine in patients with coronary artery disease and left ventricular dysfunction. Circulation 1980; 61:751-8. [PMID: 7357717 DOI: 10.1161/01.cir.61.4.751] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
To determine the hemodynamic effects of afterload reduction at rest and during upright exercise in patients with coronary artery disease and left ventricular dysfunction, 12 patients were studied before and after taking 50-75 mg of oral hydralazine every 6 hours for 48 hours. Oxygen consumption and heart rate were unchanged from control both at rest and during two work loads on a bicycle ergometer. Cardiac output was significantly increased at rest and during both workloads. The arteriovenous oxygen difference was significantly reduced at rest and during exercise. Pulmonary capillary wedge pressure was also significantly lower at rest and during exercise. Systemic vascular resistance was reduced at rest, and exercise-induced vasodilation was augmented by the administration of hydralazine. Left ventricular end-diastolic volume and ejection fraction assessed by radionuclide angiocardiography were not significantly changed at rest or during exercise after hydralazine. Seven of the 12 patients have maintained clinical improvement during a follow-up of 6-12 months. Hemodynamic improvement provided by oral hydralazine at rest is maintained during moderate exertion in patients with coronary artery disease and left ventricular dysfunction. In selected patients, chronic afterload reduction with oral hydralazine may result in increased cardiac reserve, decreased pulmonary congestion or decreased myocardial oxygen demands, thereby improving or abolishing resting or exertional dyspnea or angina.
Collapse
|
38
|
|
39
|
Rubin SA, Chatterjee K, Ports TA, Gelberg HJ, Brundage BH, Parmley WW. Influence of short-term oral hydralazine therapy on exercise hemodynamics in patients with severe chronic heart failure. Am J Cardiol 1979; 44:1183-9. [PMID: 495513 DOI: 10.1016/0002-9149(79)90186-3] [Citation(s) in RCA: 70] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Changes in left ventricular performance were evaluated in 14 patients with functional New York Heart Association class III or IV chronic heart failure before and after the addition of oral hydralazine to conventional therapy. With conventional therapy, cardiac output increased from 3.4 +/- 0.8 (mean +/- 1 standard deviation) at rest to 4.7 +/- 1.4 liters/min during exercise. This increase in cardiac output on exercise during conventional therapy was mainly due to an increase in heart rate. After the addition of hydralazine, cardiac output at rest increased to 5.0 +/- 1.4 liters/min. The increase in cardiac output was essentially due to an increase in stroke volume. This enhanced stroke volume after hydralazine therapy was maintained during exercise. Hydralazine therapy did not change either the left ventricular filling pressure at rest or the magnitude of increase in left ventricular filling pressure during exercise. Nevertheless, increased cardiac output and stroke volume with similar changes in left ventricular filling pressure during exercise indicated improved left ventricular performance after hydralazine therapy. After short-term hydralazine therapy, symptom-limited peak exercise work load, duration of exercise and maximal oxygen consumption during exercise did not increase. Clinical follow-up at 2 months after long-term therapy revealed subjective improvement in exercise tolerance in 13 of the 14 patients.
Collapse
|
40
|
Zelis R, Flaim SF, Moskowitz RM, Nellis SH. How much can we expect from vasodilator therapy in congestive heart failure? Circulation 1979; 59:1092-7. [PMID: 436201 DOI: 10.1161/01.cir.59.6.1092] [Citation(s) in RCA: 63] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
41
|
|
42
|
|